Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir in infants and children with RSV
NCT04583280Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Rilematovir with Placebo (2 arms). Primary endpoint: Percentage of Participants by Respiratory Syncytial Virus (RSV) Recovery Scale (RRS) Category at Day 8. Started Sep 2021; status: terminated.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04583280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583280.